Navigation Links
Human neural stem cells could meet the clinical problem of critical limb ischemia
Date:11/25/2013

New research has shown human neural stem cells could improve blood flow in critical limb ischemia through the growth of new vessels. Critical limb ischemia (CLI) is a disease that severely obstructs arteries and reduces the blood flow to legs and feet. CLI remains an unmet clinical problem and with an ageing population and the rise in type II diabetes, the incidence of CLI is expected to increase.

The study, led by academics in the University of Bristol's School of Clinical Sciences, is published online in the American Heart Association journal Arteriosclerosis, Thrombosis, and Vascular Biology.

Current stem cell therapy trials for the treatment of CLI have revitalised new hope for improving symptoms and prolonging life expectancy. However, there are limitations on the use of autologous cell therapy. The patient's own stem cells are generally invasively harvested from bone marrow or require purification from peripheral blood after cytokine stimulation. Other sources contain so few stem cells that ex vivo expansion through lengthy bespoke Good Manufacturing Practice processes is required. Ultimately, these approaches lead to cells of variable quality and potency that are affected by the patient's age and disease status and lead to inconsistent therapeutic outcomes.

In order to circumvent the problem a team, led by Professor Paolo Madeddu in the Bristol Heart Institute at the University of Bristol, has used a conditionally immortalised clonal human neural stem cell (hNSC) line to treat animal models with limb ischaemia and superimposed diabetes. The CTX cell line, established by stem cell company ReNeuron, is genetically modified to produce genetically and phenotypically stable cell banks.

Results of the new study have shown that CTX treatment effectively improves the recovery from ischaemia through the promotion of the growth of new vessels. The safety of CTX cell treatment is currently being assessed in disabled patients with stroke [PISCES trial, NCT01151124]. As a result, the same cell product is immediately available for starting dose ranging safety and efficacy studies in CLI patients.

Professor Paolo Madeddu, Chair of Experimental Cardiovascular Medicine and Head of Regenerative Medicine Section in the Bristol Heart Institute at the University of Bristol, said: "Currently, there are no effective drug interventions to treat CLI. The consequences are a very poor quality of life, possible major amputation and a life expectancy of less than one year from diagnosis in 50 per cent of all CLI patients.

"Our findings have shown a remarkable advancement towards more effective treatments for CLI and we have also demonstrated the importance of collaborations between universities and industry that can have a social and medical impact."

Dr John Sinden, Chief Scientific Officer of ReNeuron, added: "The novel idea of using neural stem cells to treat vascular disease arose from a chance discussion with Professor Madeddu. The discussion led to a short pilot study with our cells producing very clear data, which then developed into a further eight experiments exploring different variants of the disease model, the product formulation and dose variation.

"The study also explored the cascade of molecular events that produced vascular and muscle recovery. It is a great example of industry and academia working successfully towards the key goal, clinical translation."


'/>"/>

Contact: Joanne Fryer
joanne.fryer@bristol.ac.uk
44-011-733-17276
University of Bristol
Source:Eurekalert

Related medicine news :

1. GHS Cancer Institute and USC School of Medicine Partner on Nation’s First Human Performance Lab to Tackle Cancer Fatigue
2. Research paves path for hybrid nano-materials that could replace human tissue or todays pills
3. HUMAN Ranks #7 on Los Angeles Business Journal’s “Fastest Growing Private Companies” List with Three-Year Sales Growth of 514%
4. 2 human proteins found to affect how jumping gene gets around
5. Diet Doc Hormone Diets & Weight Loss Plans Improve Human Heart Health With Prescription Hormone Diet Plans That Help Dieters Lose Weight Fast
6. What composes the human heart? U of T researchers crunch the numbers
7. Predicting human body height from DNA
8. The human health costs of losing natural systems: Quantifying Earths worth to public health
9. China Human Vaccine Industry Report, 2012-2015
10. Mahendra Trivedi Announces the New Master During the Historical Event “Transforming Humanity”
11. NHS Human Services Foundation to Host 10th Annual Leading the Way Awards Gala
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact ... , Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning ... improve memory. The book’s publication date is March 16, 2016. A free review ...
(Date:2/10/2016)... ... February 10, 2016 , ... A national ergonomics pioneer ... Expo event March 9-11, 2016. Hosted by Ohio's Bureau of Worker's Compensation, the ... the longest running and largest worker's compensation event in Ohio, organizers of the ...
(Date:2/10/2016)... West Palm Beach, Florida (PRWEB) , ... February ... ... Golf & Country Club) announced that it has been awarded the prestigious Distinguished ... of the World award program conducted by BoardRoom magazine, one of the most ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has ... readily available to physicians. The integration will enable Allscripts users to post ... via Everseat’s free mobile app. , The partnership gives Everseat substantial added power ...
(Date:2/10/2016)... MA (PRWEB) , ... February 10, 2016 , ... ... their revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine ... provide a solution that ensures the integrity of biological samples while operating at ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 9, 2016  Until recently, the ... surgery or liposuction. Thankfully, the FDA approved the non-invasive ... to death. Coolsculpting was originally approved in 2010 for ... thighs and now the chin. With this add-on approval, ... can use a smaller applicator, the CoolMini, to address ...
(Date:2/10/2016)... 2016 On Tuesday, February 9th, the ... with its Arthritis Advisory Committee to discuss ... & Johnson,s Remicade and most likely the ... U.S. The Biologics Prescribers Collaborative (BPC) along ... for Patient Access, American Association of Clinical ...
(Date:2/10/2016)... 2016 CTI BioPharma Corp. (CTI BioPharma) ... regarding the clinical studies being conducted under the ... Following the issuance of the Company,s February 8, ... issued by the U.S. Food and Drug Administration ... an oral communication from the FDA followed by ...
Breaking Medicine Technology: